Janux Therapeutics's top three insider shareholders as of March 23, 2026 are Ventures Xi, L.P. Avalon (TenPercentOwner, 4.19Mn shares), Corp Bregua (TenPercentOwner, 3.75Mn shares), Jay Lichter (Director, 3.34Mn shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Ventures Xi, L.P. Avalon | 2,071,799 | 2,115,373 | 18 Oct, 2024 | |
| Corp Bregua | 3,749,250 | 0 | 16 Jun, 2021 | |
| Jay Lichter | 0 | 3,340,018 | 05 Jun, 2024 | |
| Tighe Reardon | Acting Chief Financial Officer | 0 | 3,340,018 | 05 Jun, 2024 |
| David Alan Campbell | President And Ceo | 381,582 | 0 | 02 Jan, 2025 |
| Advisors Llc Orbimed | 0 | 231,098 | 30 Dec, 2021 | |
| Peter A. Thompson | 0 | 231,098 | 30 Dec, 2021 | |
| Thomas Diraimondo | Chief Scientific Officer | 155,825 | 0 | 02 Jan, 2026 |
| Sheila Gujrathi | 118,889 | 0 | 13 Jun, 2025 | |
| Charles M. Winter | Chief Technical Officer | 106,321 | 0 | 02 Jan, 2026 |
| Andrew Hollman Meyer | Chief Business Officer | 83,095 | 0 | 02 Jan, 2026 |
| Janeen Noel Doyle | Chief Corp. Bus. Dev. Ofcr | 80,000 | 0 | 02 Jan, 2026 |
| Zachariah Mciver | Chief Medical Officer | 52,286 | 0 | 02 Jan, 2026 |
| William Go | Chief Medical Officer | 44,000 | 0 | 04 Feb, 2026 |
| Maria Dobek | Vice President, Accounting | 34,308 | 0 | 02 Jan, 2026 |
| Byron Robinson | Chief Strategy Officer | 28,000 | 0 | 03 Jan, 2025 |
| Natasha Hernday | 8,731 | 0 | 13 Jun, 2025 | |
| Jay Lichter | 7,000 | 0 | 24 Oct, 2024 | |
| Alana B. Mcnulty | 6,250 | 0 | 13 Jun, 2025 | |
| Capital Management, L.P. Ra | 0 | 6,250 | 13 Jun, 2025 | |
| Winston Kung | 6,250 | 0 | 13 Jun, 2025 | |
| Jake Simson | 6,250 | 0 | 13 Jun, 2025 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 02 Feb, 2026 | William Go | Common Stock | A | 44,000 | $0.00 | 44,000 | D | A |
| 02 Feb, 2026 | William Go | Stock option (right to buy) | A | 154,000 | $0.00 | 154,000 | D | A |
| 02 Jan, 2026 | Charles M. Winter | Common Stock | D | 2,401 | $13.73 | 77,721 | D | S |
| 02 Jan, 2026 | Andrew Hollman Meyer | Common Stock | D | 1,879 | $13.73 | 83,095 | D | S |
| 02 Jan, 2026 | Zachariah Mciver | Common Stock | D | 2,714 | $13.73 | 23,286 | D | S |
| 02 Jan, 2026 | Maria Dobek | Common Stock | D | 1,462 | $13.73 | 15,373 | D | S |
| 02 Jan, 2026 | Janeen Noel Doyle | Common Stock | A | 36,000 | $0.00 | 80,000 | D | A |
| 02 Jan, 2026 | Thomas Diraimondo | Common Stock | D | 2,505 | $13.73 | 124,425 | D | S |
| 02 Jan, 2026 | Thomas Diraimondo | Common Stock | A | 31,400 | $0.00 | 155,825 | D | A |
| 02 Jan, 2026 | Maria Dobek | Common Stock | A | 18,935 | $0.00 | 34,308 | D | A |
| 02 Jan, 2026 | Janeen Noel Doyle | Stock option (right to buy) | A | 126,000 | $0.00 | 126,000 | D | A |
| 02 Jan, 2026 | Charles M. Winter | Common Stock | A | 28,600 | $0.00 | 106,321 | D | A |
| 02 Jan, 2026 | Zachariah Mciver | Common Stock | A | 29,000 | $0.00 | 52,286 | D | A |
| 02 Jan, 2026 | Maria Dobek | Stock option (right to buy) | A | 42,600 | $0.00 | 42,600 | D | A |
| 02 Jan, 2026 | Charles M. Winter | Stock option (right to buy) | A | 100,100 | $0.00 | 100,100 | D | A |
| 02 Jan, 2026 | Thomas Diraimondo | Stock option (right to buy) | A | 109,900 | $0.00 | 109,900 | D | A |
| 02 Jan, 2026 | Zachariah Mciver | Stock option (right to buy) | A | 101,500 | $0.00 | 101,500 | D | A |
| 01 Dec, 2025 | Andrew Hollman Meyer | Common Stock | A | 3,333 | $10.59 | 88,307 | D | M |
| 01 Dec, 2025 | Andrew Hollman Meyer | Common Stock | D | 2,700 | $32.85 | 85,607 | D | S |
| 01 Dec, 2025 | Andrew Hollman Meyer | Common Stock | D | 633 | $33.52 | 84,974 | D | S |